APUS
Apimeds Pharmaceuticals US, Inc.
Key Financials
Net Income
$-1389990
↓ 78.7%
Operating Income
$-1275095
↓ 70.6%
EPS (Diluted)
$-0.18
↓ 5.9%
Shareholders' Equity
$-1358121.00
↓ 4361.6%
Total Assets
$13057.00
↓ 96.9%
Total Liabilities
$1.4M
↑ 251.4%
Cash & Equivalents
$3455.00
↓ 99.2%
Operating Cash Flow
$-733526.00
↓ 16.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | APUS |
| Company Name | Apimeds Pharmaceuticals US, Inc. |
| CIK | 1894525 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 848-201-5010 |